Business Wire

Mercans Launches Groundbreaking AI Suite, Redefining Payroll as an Intelligent, Always-On Business Function

6.10.2025 10:05:00 CEST | Business Wire | Press Release

Share

Mercans, a global leader in payroll technology and managed payroll services, today unveiled a sweeping suite of AI-powered innovations that mark a historic shift in the payroll industry. With this launch, Mercans positions itself not as a company with AI features, but as an AI-first organization, embedding intelligence into the very core of payroll, compliance, and client experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006939644/en/

AI-powered payroll. Smarter. Faster. Always compliant (Graphic: AETOSWire)

“Payroll has long been seen as a back-office necessity. We are turning it into a front-line strategic advantage. By putting AI at the center of our platform, we’re delivering accuracy, compliance, and insights at a scale and speed never before possible. This is not just about functionality - it’s about redefining payroll’s role in business.”
- Tatjana Domovits, Group CEO of Mercans.

Paradigm Shift In How Payroll Is Run And Experienced

Mercans is transforming the payroll experience with a suite of AI capabilities that redefines how payroll is calculated, validated, reported, and understood.

Central to this transformation is Instaroll™, the company’s real-time payroll orchestration engine that allows organizations to simulate, calculate, and adjust payroll instantly. Employees can now see their earnings outcomes as they happen, while finance leaders gain unparalleled visibility into workforce costs. With Instaroll™, payroll moves from a rigid monthly cycle into a dynamic, on-demand process.

One of the most powerful demonstrations of Mercans’ AI-first vision is I/O Validation, a feature built into the core platform and available to all clients. It is a true game changer because it solves one of payroll’s most persistent pain points: ensuring that what goes in and what comes out of payroll is always correct. Traditional payroll systems rely on rigid rule-based checks that often miss contextual errors - a misplaced overtime calculation, an incorrect tax rate, or a mismatched contribution. With AI-driven I/O Validation, these issues are detected instantly. The system continuously learns from payroll patterns, cross-checks both inputs and outputs, and flags anomalies before they reach employees or regulators.

By embedding this intelligence natively into the platform, Mercans makes proactive accuracy a guaranteed standard for every Managed Payroll and SaaS client. This is not an add-on, it is a practical application of AI that delivers trust, saves time, and eliminates costly mistakes.

Another breakthrough AI capability in the Mercans platform is Custom Reporting AI, which transforms payroll data from static numbers into living intelligence. Instead of being limited to pre-defined templates, leaders can simply ask the system questions in natural language such as “Show me overtime costs by region for the past three quarters”, and instantly receive tailored, interactive reports. The AI doesn’t just fetch data; it interprets patterns, highlights anomalies, and presents findings in executive-ready formats.

This means payroll data is no longer a historical record, it becomes a forward-looking decision-making tool. Combined with Mercans’ built-in I/O Validation, which ensures that the data itself is accurate, Custom Reporting AI makes payroll not only correct but also actionable. Executives can spot workforce trends, anticipate risks, and model financial impacts with confidence, turning payroll from a compliance task into a strategic intelligence engine.

On the employee side, one of the most visible and practical applications of Mercans’ AI is the Payslip Interpretation Assistant. Available 24/7, this AI companion translates complex payslips into clear, simple language - explaining taxes, deductions, and allowances in a way that anyone can understand. What used to be a source of confusion and repeated HR queries is now resolved instantly, on demand.

Compliance Without Borders

Regulatory compliance remains one of the most formidable challenges for global enterprises. With Mercans’ AI Compliance Hub, clients now benefit from real-time monitoring of legislation across the globe. This AI-driven system not only interprets legal changes but proactively guides organizations to remain ahead of regulatory risks.

Complementing this is the Statutory Filing Status & Summary Assistant, which gives finance leaders instant visibility into filing obligations across jurisdictions. Whether it’s a quarterly tax submission in Europe or a statutory report in Asia, AI ensures deadlines and statuses are tracked with precision, transforming compliance from reactive firefighting into proactive assurance.

Intelligent Support, Always Available

In addition to transforming payroll operations, Mercans has embedded AI into its support ecosystem. The company has launched dedicated AI Agents for Technical and Product Support, designed to provide immediate, intelligent responses to client inquiries. These agents not only resolve issues in real time but also escalate complex cases intelligently, dramatically reducing resolution times and enhancing customer satisfaction. For clients, this means uninterrupted operations and a support experience that feels less like troubleshooting and more like a partnership.

The Mercans Advantage

The cumulative impact of these innovations is profound. For Managed Payroll clients, it means lower costs, fewer errors, and proactive compliance, delivered with intelligence at every step. For SaaS platform clients, it represents a new era of self-service, where AI copilots provide instant insights, compliance takes care of itself, and payroll becomes a strategic lever rather than a burdensome process.

“Payroll has always been about compliance and accuracy. Today, it is about intelligence, foresight, and empowerment,” added Tatjana Domovits, Group CEO of Mercans. “We are not just keeping pace with change - we are leading it. Mercans is unstoppable in its mission to transform payroll into the most intelligent business function of the future.”

About Mercans

Mercans is a leading global payroll technology company, delivering compliant, efficient, and scalable payroll solutions to multinational organizations. With a relentless focus on innovation, automation, and client success, Mercans continues to set the benchmark for the future of payroll. visit www.mercans.com
LinkedIn

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006939644/en/

Contacts

Mohsin Khan -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.c
om%2Fin%2Fmohsin000%2F&esheet=54334007&newsitemid=20251006939644&lan=en-US&ancho
r=Mohsin+Khan&index=4&md5=760ec0481ea15120299a80cb487cd934
hello@mercans.com
Berkeley Square House, 2nd Floor, Berkeley Square, London, UK.

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye